One year ago, AbbVie’s Cambridge Research Center in Cambridge, Massachusetts, U.S.A., officially opened its doors. Inside the 43,000-square-foot facility, our scientists are working in exciting areas of disease biology, such as tau and neuroregeneration, in the hopes of identifying compelling targets that ultimately will help us discover new medicines to treat patients with Alzheimer’s disease. These scientific insights may also help us one day address other neurodegenerative diseases, such as Parkinson’s and multiple sclerosis, among others.
Take a look inside our new facility with Robert Talanian, Ph.D., director of in vitro pharmacology at the Cambridge Research Center.
Learn more about AbbVie’s broader discovery efforts in neuroscience.
Media inquiries:
Jaquelin Finley
Email: jaquelin.finley@abbvie.com
Call: + 1 847-937-3998
